Related references
Note: Only part of the references are listed.A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial
Daisuke Tomizawa et al.
BLOOD (2020)
A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia
C. Michel Zwaan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study
Rob Pieters et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia
Andrei V. Krivtsov et al.
CANCER CELL (2019)
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
Steven Knapper et al.
BLOOD (2017)
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Todd M. Cooper et al.
CLINICAL CANCER RESEARCH (2016)
Decreased Induction Morbidity and Mortality Following Modification to Induction Therapy in Infants With Acute Lymphoblastic Leukemia Enrolled on AALL0631: A Report From the Children's Oncology Group
Wanda L. Salzer et al.
PEDIATRIC BLOOD & CANCER (2015)
Intensified Chemotherapy Without Sct in Infant All: Results From COG P9407 (Cohort 3)
ZoAnn E. Dreyer et al.
PEDIATRIC BLOOD & CANCER (2015)
Does hematopoietic stem cell transplantation benefit infants with acute leukemia?
Edward Allan R. Sison et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Treatment of infant leukemias: challenge and promise
Patrick Brown
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study
Huining Kang et al.
BLOOD (2012)
Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+and MLL-germline acute lymphoblastic leukemia
M. C. Chillon et al.
LEUKEMIA (2012)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
Analysis of the Role of Hematopoietic Stem-Cell Transplantation in Infants With Acute Lymphoblastic Leukemia in First Remission and MLL Gene Rearrangements: A Report From the Children's Oncology Group
Zoann E. Dreyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants
Ronald W. Stam et al.
BLOOD (2010)
Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study
Georg Mann et al.
BLOOD (2010)
Toxicity Assessment of Molecularly Targeted Drugs Incorporated into Multiagent Chemotherapy Regimens for Pediatric Acute Lymphocytic Leukemia (ALL): Review From an International Consensus Conference
Terzah M. Horton et al.
PEDIATRIC BLOOD & CANCER (2010)
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol
V. H. J. Van der Velden et al.
LEUKEMIA (2009)
Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia
Ronald W. Stam et al.
BLOOD (2007)
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial
Rob Pieters et al.
LANCET (2007)
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)
Kirk R. Schultz et al.
BLOOD (2007)
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Mark Levis et al.
BLOOD (2006)
Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner
P. Brown et al.
LEUKEMIA (2006)
Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group
Joanne M. Hilden et al.
BLOOD (2006)
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia
RW Stam et al.
BLOOD (2005)
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression
P Brown et al.
BLOOD (2005)
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy
T Taketani et al.
BLOOD (2004)
Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition
P Brown et al.
BLOOD (2004)
In vitro studies of a FM inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
M Levis et al.
BLOOD (2004)
Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification
SA Armstrong et al.
CANCER CELL (2003)
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
SA Armstrong et al.
NATURE GENETICS (2002)
Share Paper
